BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program

reuters11-07

BRIEF-Viracta <a href="https://laohu8.com/S/LENZ">Therapeutics</a> announces reprioritization of resources to enhance focus on Nana-Val development program

Nov 6 (Reuters) - Viracta Therapeutics Inc VIRX.O:

VIRACTA THERAPEUTICS ANNOUNCES REPRIORITIZATION OF RESOURCES TO ENHANCE FOCUS ON NANA-VAL DEVELOPMENT PROGRAM IN PATIENTS WITH RELAPSED OR REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMA
VIRACTA THERAPEUTICS INC: IMPLEMENTS 42% WORKFORCE REDUCTION

Source text: ID:nGNX4wNrZM

Further company coverage: VIRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481665059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 06:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481665059","market":"us","top_or_hot":-1,"title":"BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announces reprioritization of resources to enhance focus on Nana-Val development program</title></head><body><p><span>Nov 6 (Reuters)</span><span> - </span>Viracta Therapeutics Inc <span>VIRX.O</span>:</p><ul><li><p>VIRACTA THERAPEUTICS ANNOUNCES REPRIORITIZATION OF RESOURCES TO ENHANCE FOCUS ON NANA-VAL DEVELOPMENT PROGRAM IN PATIENTS WITH RELAPSED OR REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMA</p></li><li><p>VIRACTA THERAPEUTICS INC: IMPLEMENTS 42% WORKFORCE REDUCTION</p></li></ul><p>Source text: <span>ID:nGNX4wNrZM</span></p><p>Further company coverage: <span>VIRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 06:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUAC5GBWW:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development programNov 6 (Reuters) - Viracta Therapeutics Inc VIRX.O:VIRACTA THERAPEUTICS ANNOUNCES ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUAC5GBWW:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIRX","symbol_name":"Viracta Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUAC5GBWW:1","article_id":"2481665059","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481665059","pubTimestamp":1730932630,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development programNov 6 (Reuters) - Viracta Therapeutics Inc VIRX.O:VIRACTA THERAPEUTICS ANNOUNCES REPR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIRX":"Viracta Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Viracta Therapeutics宣布重新确定资源优先顺序，以加强对Nana-Val开发计划的关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIRX":0.9},"content_text":"BRIEF-Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development programNov 6 (Reuters) - Viracta Therapeutics Inc VIRX.O:VIRACTA THERAPEUTICS ANNOUNCES REPRIORITIZATION OF RESOURCES TO ENHANCE FOCUS ON NANA-VAL DEVELOPMENT PROGRAM IN PATIENTS WITH RELAPSED OR REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMAVIRACTA THERAPEUTICS INC: IMPLEMENTS 42% WORKFORCE REDUCTIONSource text: ID:nGNX4wNrZMFurther company coverage: VIRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481665059"}